While more research is needed to fully understand its functions and prognostic significance in different cancer types, CD133 has been recognized as a marker of CSCs in brain tumors, prostate cancers, and colon cancers, impacting patient survival outcomes (Mia-Jan et al., 2013; Zhang et al., 2016). This evidence concerns the gene PROM1 and cancer.